Why the study?
Does systemic anticoagulation reduce VTE recurrence or death in symptomatic patients with subsegmental pulmonary embolism?
Does systemic anticoagulation reduce VTE recurrence or death in symptomatic patients with subsegmental pulmonary embolism?
In patients with subsegmental pulmonary embolism, pooled observational data show no increase in VTE recurrence or death rates when anticoagulation is withheld, suggesting clinical equipoise.
Anticoagulation for SSPE shows clinical equipoise in observational data; leaves open the need for randomized trials to guide practice.
Background This systematic review addresses the controversy over the decision to anticoagulate patients with subsegmental pulmonary embolism ( SSPE ). Methods We searched Ovid MEDLINE , PubMed, Embase, the Cochrane Library, Scopus, Web of Science, ClinicalTrials.gov, Google Scholar, and bibliographies in March 2017. Two authors reviewed and retained papers with symptomatic patients who underwent computerized tomographic pulmonary angiography and had sufficient information to determine SSPE ; decision to treat (or not) with systemic anticoagulation; and outcomes of bleeding, venous thromboembolism ( VTE ) recurrence, and death. Papers were assessed for selection and publication bias and heterogeneity, with Eggers and the inconsistency indexes (I 2 ). Results From 1,512 papers screened, we included 14 studies comprising 15,563 patients for full‐length review and analysis. Pooled data demonstrated I 2 = 99% with an Eggers p < 0.001, suggesting significant publication bias. The pooled prevalence of SSPE was 4.6% (95% confidence interval [ CI ] = 1.8%–8.5%). The frequency of bleeding in SSPE patients treated with anticoagulation ( n = 589) was 8.1% (95% CI = 2.8%–15.8%), with no available bleeding data in untreated patients ( n = 126). The frequency of VTE recurrence within 90 days was 5.3% (95% CI = 1.6%–10.9%) for treated versus 3.9% (95% CI = 4.8%–13.4%) for untreated, while the frequency of death was 2.1% (95% CI = 3.4%–5.2%) for treated versus 3.0% (95% CI = 2.8%–8.6%) for untreated. Conclusion This systematic review highlights the lack of any clinical trial to make a clear inference about harm or benefit of anticoagulation for SSPE . Comparison of pooled data from uncontrolled outcome studies shows no increase in VTE recurrence or death rates for patients who were not anticoagulated. These data suggest clinical equipoise for decision to anticoagulate or not anticoagulate patients with SSPE . However, this inference is limited by small numbers, imprecision, and the lack of a controlled clinical trial.
No takes yet. Share an insight, caveat, or question.
Bariteau et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: